Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 197.00
Change Today +0.60 / 0.31%
Volume 4.0K
ETVW On Other Exchanges
Tel Aviv
As of 3:36 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

e.t view medical ltd (ETVW) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/1/15 - $520.00
52 Week Low
08/25/15 - $190.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for E.T VIEW MEDICAL LTD (ETVW)

Related News

No related news articles were found.

e.t view medical ltd (ETVW) Related Businessweek News

No Related Businessweek News Found

e.t view medical ltd (ETVW) Details

ETView Medical Ltd. provides high-resolution video imaging systems to medical professionals in North America, South America, Europe, Asia, and Africa. The company offers VivaSight-SL, a sterile, single-use, single-lumen airway tube with an integrated high-resolution imaging camera that provides continuous airway visualization and unparalleled control for improved airway management; VivaSight-DL, a sterile, single-use double lumen airway tube with an integrated high-resolution imaging camera; and VivaSight endobronchial blocker, which consists of a sterile, single-use, steerable balloon-tipped catheter that is guided using video imaging in real time to a selected bronchial segment to affect balloon blockage of the distal airway. It also provides various accessories, including medical-grade LCD monitors, power supply and adapter kits, monitor tripods, extension cables, RCA cables for external monitors, and BNC males to RCA female adapters. The company is based in Misgav, Israel.

e.t view medical ltd (ETVW) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 429.0K
Chief Operating Officer
Total Annual Compensation: 376.0K
Vice President of Sales
Total Annual Compensation: 415.0K
Compensation as of Fiscal Year 2013.

e.t view medical ltd (ETVW) Key Developments

ETView Reports Multi-Center Clinical Evaluation Results for VivaSight

ETView Medical Ltd. announced results of a multi-center clinical report on the use of VivaSight to achieve One Lung Ventilation (OLV). As reported in the April, 2015 issue of Anaesthesia, investigators at VU University Medical Centre, Amsterdam, The Netherlands; Medical Centre Alkmaar, Alkmaar, The Netherlands; Catharina Hospital, Eindhoven, The Netherlands; and Rambam Health Care Campus, Haifa, Israel, reported on “Evaluation of a new double-lumen endobronchial tube with an integrated camera (VivaSight DL): a prospective multicentre observational study,” which was performed on 151 patients. The objectives of the evaluation were to monitor correct placement of VivaSight DL to achieve OLV, measure flexible fiberoptic bronchoscopy utilization during OLV, and monitor postoperative complaints. The current standard of practice requires the use of flexible fiberoptic bronchoscopy to verify placement of endotracheal tubes during OLV procedures. According to the investigators of the current evaluation, correct placement of VivaSight™ DL was achieved in 148 (98%) patients. Of the 148 successful VivaSight™ DL tube placements, lung collapse was achieved in 147 (99%). As noted following the evaluation, no major complications occurred during VivaSight™ DL placement or throughout the surgical procedure. The authors reported an 87% reduction in fiberoptic bronchoscopy when VivaSight DL was employed for OLV, similar to a prior published study2 describing a reduction of 93% in the use of fiberoptic bronchoscopy for OLV cases when VivaSight™ DL was employed. The reduced use of fiberoptic bronchoscopy in the current evaluation was associated with several clinical and economic advantages by the authors. Clinically, the authors identified patients with reduced pulmonary reserve, wherein use of fiberoptic bronchoscopy may lead to hypoxaemia and hypercarbia. Economic analysis by one center (University Medical Center) demonstrated saving of €12,000/$16,000 for every 100 OLV cases where VivaSight DL was employed.

ETView Medical Ltd. Enters into Distribution Agreement with Well Lead Medical Co., Ltd

ETView Medical Ltd. announced that it has entered into a distribution agreement with Well Lead Medical Co., Ltd. The agreement enables Well Lead to market ETView's VivaSight 1 DL platform, combining an airway ventilation tube with integrated continuous high resolution airway imaging for patient airway control and One Lung Ventilation (OLV) capability in China.

ETView Reports on Clinical Evaluation of VivaSight

ETView Medical Ltd. announced a clinical report on the use of VivaSight to achieve single lung isolation. As reported in the January, 2015 issue of the Canadian Journal of Anesthesia, investigators at University Hospital Zurich, (Zurich, Switzerland) reported on Intubation With VivaSight Or Conventional Left-Sided Double-Lumen Endotracheal Tubes (DLT): A Randomized Trial" which was performed on 40 patients. The primary objective of the investigation was to evaluate time to intubation. Secondary objectives focused on VivaSight insertion success without the need for flexible fiberoptic bronchoscopy during One Lung Ventilation (OLV), frequency of tube displacement, ease of insertion, quality of lung collapse, postoperative complaints, and airway injuries. The current standard of practice requires the use of flexible fiberoptic bronchoscopy to verify placement of endotracheal tubes during OLV procedures. Recent literature suggests associated flexible fiberoptic bronchoscope expenses from $1,002 up to $2,803 per surgical case. According to the investigators of the current study, flexible fiberoptic bronchoscopy was eliminated when utilizing VivaSight to achieve OLV, compared with flexible fiberoptic bronchoscopy required in 100% of the cases which employed standard DLT to achieve OLV. Flexible fiberoptic bronchoscopy confirmed that in 15% of cases a standard DLT was misplaced during initial intubation, whereas no such cases occurred with the use of VivaSight- which the authors attributed to continuous visualization capabilities which are an integrated feature of VivaSight. Four of the conventional endotracheal tubes became displaced during placement and another two during surgical lung manipulation, each requiring repositioning under flexible fiberoptic bronchoscopy. In the VivaSight group repositioning was successful without the use of flexible fiberoptic bronchoscopy when tube displacement was detected in two patients during placement and in three during surgical lung manipulation. The authors referenced earlier citations noting that standard endotracheal tubes often become displaced after repositioning patients from the supine (intubating) to the lateral (operating) position. If not promptly identified and remedied, displacements can result in life-threatening complications and airway lacerations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ETVW:IT 197.00 +0.60

ETVW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ETVW.
View Industry Companies

Industry Analysis


Industry Average

Valuation ETVW Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact E.T VIEW MEDICAL LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at